CAPABILITIES · SPECIALIST SAMPLE MATRICES · NASAL LINING FLUID

Direct sampling of the upper airway

Nasal lining fluid captures the local immune signature where allergen, virus and pollutant first meet the host, without a needle, a scope or a clinic visit.

Talk to a scientist about your matrix

Request a feasibility pilot

CAPABILITIES · SPECIALIST SAMPLE MATRICES · NASAL LINING FLUID

Direct sampling of the upper airway

Nasal lining fluid captures the local immune signature where allergen, virus and pollutant first meet the host, without a needle, a scope or a clinic visit.

Talk to a scientist about your matrix

Request a feasibility pilot

70 to 80% panel detectability in nasal swabs

70 to 80% panel detectability in nasal swabs

70 to 80% panel detectability in nasal swabs

Microlitre inputs after elution dilution

Microlitre inputs after elution dilution

Microlitre inputs after elution dilution

Nasal swab residual material often usable

Nasal swab residual material often usable

Nasal swab residual material often usable

HTA licensed, GCP compliant

HTA licensed, GCP compliant

HTA licensed, GCP compliant

Start with your markers and your protocol

Send us the markers that matter, your collection device, your elution buffer and your expected volumes. We will tell you which markers are realistically detectable after elution dilution, what the study will need, and whether a pilot is the right first step. We answer within one working day.

If you have not fixed your collection protocol yet, start there. Collection sets the ceiling on what any platform can measure.

Send us your marker list

WHAT IS nasal lining fluid

Local immune biology, sampled non-invasively

Nasal lining fluid carries the local immune signature of the nasal epithelium: cytokines, chemokines and soluble mediators at the site where allergen, virus and pollutant first interact with the host.

Collection is quick, well tolerated, repeatable in the same participant, and practical in children. That opens study designs which are difficult or impossible with venepuncture or invasive respiratory sampling.

The analytical problem is that the same sample is close to undetectable on a conventional immunoassay.

THE CHALLENGE

Why nasal lining fluid defeats most assays

Elution dilution

Samples are washed off the collection strip into buffer, diluting them several-fold. The amount absorbed also varies between people, nostrils and visits, so the true dilution is never precisely known.

Buffer interference

Elution needs detergent to release proteins and protease inhibitors to protect them. Both are necessary, and the assay has to tolerate both.

The result

Samples reach the assay dilute, in detergent, with an uncertain dilution factor. Conventional ELISA returns non-detects, and a standard multiplex can use the whole sample on a few markers and still come back empty.

Too often, a valuable sample is abandoned for blood, which answers a different question.

our approach

Enough sensitivity to survive the dilution

Nasal lining fluid has been shown to work on an ultra-sensitive platform built for exactly this problem: small, dilute, buffer-borne samples that need breadth and sensitivity at once.

1. Barcoded antibodies

Each antibody pair carries a DNA tag.

2. Capture and wash

Detergent, buffer and other interfering material are washed away before measurement.

3. Attomolar sensitivity

Counting barcodes detects proteins at levels where elution would push them below detection on a conventional assay.

What the published data shows

In nasal swabs, 175 to 200 of 250 inflammatory proteins (70 to 80%) were detected, higher than in sputum.

No equivalent figure has been published for absorptive strips, which add their own elution step, so the swab figure shouldn’t be read across.

We establish what strips give for your markers in a pilot, on your own protocol.

how it works

What you gain

Non-invasive

No needle, no scope, no invasive airway procedure.

Repeatable

Repeated sampling in the same participant, which longitudinal mucosal immunology requires.

Paediatric-friendly

Practical where blood sampling creates a recruitment or study-design barrier.

Suited to dense sampling schedules

Viable for daily or per-visit collection across a challenge study or an exposure window.

Decentralised designs

Nasal sampling supports remote and decentralised collection in ways venepuncture and bronchoscopy cannot.

Protocol input before you collect

We advise on device, dwell time and elution buffer before a study starts, while the choices are still open.

Talk to a scientist about your matrix

NASAL SWABS

Samples you may already have

Brush and swab sampling gives a related but distinct view of the same surface, and also works on the platform.

A typical workflow

Brush each nostril with a separate cytobrush.

Profile amyloid, multiple tau species, NfL, GFAP, synaptic proteins and neuroinflammatory mediators from a single CSF or plasma draw.

Used in Alzheimer’s disease, ALS, frontotemporal dementia, Parkinson’s disease, Lewy body disease and rare neurological disorders.

Wash both into a few millilitres of PBS.

Centrifuge gently to clear cells and debris.

Store the supernatant at −80°C.

Don’t discard leftover material

If your study already collects nasal swabs for virology or transcriptomics, the residual material is often enough to add a protein readout, with no extra collection burden.

Ask us before you throw it away.

Talk to a scientist about your matrix

HOW IT WORKS

How the sample reaches us

1. Collection

2. Elution

3. Processing

4. Study consistency

Before you fix your protocol

If you are designing a collection protocol from scratch, talk to us before you finalise it. The decisions made at collection set the ceiling on what any platform can measure afterwards, and they cannot be undone at analysis.


WHAT TO USE

Choosing a panel

Nasal work centres on the cytokines, chemokines and immune mediators of the mucosal surface, measured in a single run from a single sample.

NULISAseq™ Inflammation Panel 250

NULISAseq Immune 340 Panel

NULISAseq Inflammation Panel 250 AQ

Simoa® or MSD®

Typical programmes

The default for nasal work: cytokines, chemokines and soluble immune mediators.

NULISAseq™ Inflammation Panel 250

NULISAseq Immune 340 Panel

NULISAseq Inflammation Panel 250 AQ

Simoa® or MSD®

Typical programmes

The default for nasal work: cytokines, chemokines and soluble immune mediators.

Sample requirements

  • Collection device: synthetic absorptive matrix strip, or cytobrush for swab sampling. Tell us which and we will work to it.

  • Dwell time: short and defined. Record it, and keep it consistent across the study.

  • Elution buffer: PBS with low-concentration detergent such as 0.05% Tween-20, plus protease inhibitors. Record the exact composition.

  • Volume to ship: set by the assay rather than by the matrix. Ship what your assay requires plus roughly 10 µL of dead volume, so a repeat stays possible. Tell us your elution buffer volume and typical recovery and we will confirm the usable volume of eluate at scoping.

  • Processing: centrifuged, supernatant retained.

  • Aliquoting: single-use aliquots.

  • Freeze and thaw: as few cycles as possible, and within the limit for the platform you will run: up to three to five cycles on NULISA depending on panel, three to four on Simoa, two on MSD.

  • Storage: −80°C.

  • Shipping: on dry ice, with a manifest listing sample ID, volume, elution buffer, dilution factor, nostril, collection date and freeze and thaw history.


Nostril and dwell time matter here in a way they do not in plasma. Record both.

These are recommendations, not conditions. If your protocol is already validated, tell us what it is and we will design around it.

We confirm receipt and condition in writing within two working days, before anything is consumed.

Shipping samples internationally

We can arrange collection and shipping, or work with your preferred courier. Either way we confirm the logistics, temperature control and documentation at scoping, before any samples move.

Why you can trust this now

Alamar's published data puts nasal swabs at 175 to 200 of 250 targets, 70 to 80%, on the Inflammation Panel 250. That figure is for swabs.


There is no published figure for absorptive strip collection, and we will neither quote a number we cannot cite nor predict one we have not measured.


What strips give for your markers is something we establish on your protocol.

We run Simoa on the SR-X alongside NULISA, MSD and sequencing.

All of them are ours, so the recommendation you get is a scientific one. If your target is better served by NULISA or MSD we will say so, and the work stays with us either way.



Homebrew development means we are not limited to the catalogue.


Where no commercial Simoa assay exists for your target, we can build one.

THE ALTHEOME DIFFERENCE

Why partner with Altheome on nasal lining fluid

Specialist matrix work demands sensitivity capable of resolving a fraction of the analyte concentration found in blood, matrix-specific validation, and the willingness to develop a workflow where none exists commercially. That is the work we ask for.

Feasibility before commitment

Protocol input before you collect

Normalisation strategy

Honest panel selection

Matrix development

Confidentiality

A single-plate pilot, to test the matrix before committing a full cohort.

Talk to a scientist

THE ALTHEOME DIFFERENCE

Why partner with Altheome on nasal lining fluid

Specialist matrix work demands sensitivity capable of resolving a fraction of the analyte concentration found in blood, matrix-specific validation, and the willingness to develop a workflow where none exists commercially. That is the work we ask for.

Feasibility before commitment

Protocol input before you collect

Normalisation strategy

Honest panel selection

Matrix development

Confidentiality

A single-plate pilot, to test the matrix before committing a full cohort.

Talk to a scientist

THE ALTHEOME DIFFERENCE

Why partner with Altheome on nasal lining fluid

Specialist matrix work demands sensitivity capable of resolving a fraction of the analyte concentration found in blood, matrix-specific validation, and the willingness to develop a workflow where none exists commercially. That is the work we ask for.

Feasibility before commitment

Protocol input before you collect

Normalisation strategy

Honest panel selection

Matrix development

Confidentiality

A single-plate pilot, to test the matrix before committing a full cohort.

Talk to a scientist

Discuss your matrix with a scientist

Send us your markers, collection device, elution buffer and expected volumes. We’ll advise you what’s realistically detectable, which panel fits and whether a pilot is the right first step.

Talk to a scientist about your matrix

Request a feasibility pilot

You will hear from us within one working day.

You will hear from us within one working day.

Related plataforms
Related matrices
Related applications

Still curious? Find answers in our FAQ's.

FAQ page

Related plataforms
Related matrices
Related applications

Still curious? Find answers in our FAQ's.

FAQ page